Keith Manchester - May 25, 2022 Form 4 Insider Report for Arbutus Biopharma Corp (ABUS)

Role
Director
Signature
/s/ David C. Hastings as attorney-in-fact for Keith S. Manchester
Stock symbol
ABUS
Transactions as of
May 25, 2022
Transactions value $
$0
Form type
4
Date filed
5/26/2022, 04:10 PM
Previous filing
Oct 1, 2021
Next filing
Sep 19, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABUS Stock Option (Right to Buy) Award $0 +41K $0.00 41K May 25, 2022 Common Shares 41K $2.25 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on May 25, 2022, the date of the grant.
F2 The option is fully vested and exercisable as of the date of the grant.